卡托普利与氯沙坦合用对冠心病患者血液细胞因子的影响

中国临床药理学与治疗学 ›› 2002, Vol. 7 ›› Issue (2): 159-161.

卡托普利与氯沙坦合用对冠心病患者血液细胞因子的影响

梁绪国, 潘其兴¹

山东烟台毓璜顶医院心内科, 烟台 264001;
¹山东大学齐鲁医院心内科, 济南 250012

收稿日期:2001-12-14 修回日期:2002-01-30 出版日期:2002-04-26 发布日期:2020-11-27
通讯作者: 梁绪国, 男, 博士生。Tel:0535-6258009 　E-mail:liangxuguo@yahoo.com.cn
作者简介:潘其兴, 男, 博士生导师。

Combination effect of captopril and losartan on cell adhesion molecules and cytokines in the patients with coronary heart disease

LIANG Xu-Guo, PAN Qi-Xing¹

Department of Cardiology, Yuhuangding Hospital, Yantai 264001;
¹Department of Cardiology, Qilu Hospital, Shandong University, Jinan 250012

Received:2001-12-14 Revised:2002-01-30 Online:2002-04-26 Published:2020-11-27

摘要/Abstract

摘要： 目的: 探讨卡托普利与氯沙坦合用对冠心病人可溶性细胞间粘附分子-1(sICAM-1)、可溶性血管细胞粘附分子-1(sVCAM-1)、肿瘤坏死因子-α(TNF-α) 和转化生长因子β(TGF-β) 的影响。方法: 用酶联免疫吸附法和放免法测定冠心病患者治疗前后sICAM-1、sVCAM-1、TNF-α和TGF-β 的变化。结果: 在常规治疗基础上应用卡托普利和氯沙坦的病人在临床症状改善的同时, sICAM-1、TNF-α明显降低, 与常规治疗组相比, 差异具有显著性;sVCAM-1 有降低趋势, 但差异无显著性, TGF-β 水平则不同程度的升高。结论: 卡托普利与氯沙坦合用对粘附分子和细胞因子有一定的调节作用。

关键词: 卡托普利, 氯沙坦, 粘附分子, 细胞因子, 冠心病

Abstract: AIM: To explore the effect of the combination of captopril and losartan on the sICAM-1, sVCAM-1, TNF-α, and TGF-β in the patients with coronary heart disease.METHODS: sICAM-1, sVCAM-1 and TGF-β were measured with ELISA, and TNF-αwas measured with RIA in the patients with or without the treatment of captopril and losartan.RESULTS: sICAM-1 and TNF-α decreased, and TGF-β increased distinctly in the patients given a combination of captopril and losartan compared with patients without the drugs.sVCAM-1 had the tendency of decrease in combined therapy, but no significant difference showed compared with the control patients. .CONCLUSION: The combination of captopril and losartan has the effects on the cell adhesion molecules and cytokins in patients with coronary heart disease.

Key words: captopril, losartan, cell adhesion molecules, cytokins, coronary heart disease

中图分类号:

R969.4
R452

梁绪国, 潘其兴. 卡托普利与氯沙坦合用对冠心病患者血液细胞因子的影响[J]. 中国临床药理学与治疗学, 2002, 7(2): 159-161.

LIANG Xu-Guo, PAN Qi-Xing. Combination effect of captopril and losartan on cell adhesion molecules and cytokines in the patients with coronary heart disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(2): 159-161.

参考文献

1 Blaufarb IS, Sonnenblick.The rein-angiotensin system in left ventricular remodeling[J].Am J Cardiol, 1996, 77:8c-16c
2 Liu YH, Yang XP, Sharov VG, et al.Effect of angiotensinconverting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure.Role of kinins and angiotensin II type 2 receptors[J].J Clin Invest, 1997, 99:1926-35
3 Yang BC, Phillips MI, Ambuehl PEJ, et al.Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts[J].Circulation, 1997, 96: 922-6
4 Ambrose J, Pribnow DG, Girand GD, et al.Angiotensin II type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle[J].J Am Soc Nephrol, 1999, 10:129-36
5 Crea F, Biassucci LM, Buffon A, et al.Role of inflammation in the pathogenesis of unstable coronary artery disease[J].Am J Cardiol, 1997, 80(5A):10E-6E
6 Van der Wal AC, Becker AE, van der Loos CM, et al.The site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology[J].Circulation, 1994, 89:36-44
7 Jovinge S, Hultardh-Nilson A, Regnstrom J, et al.TNF-αactivates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta[J].Arterioscler Thromb Vasc Biol, 1997, 17:490-7
8 Bray P, Agrotis A, Bobik A.Transforming growth factor-beta and receptor tyrosine-activating growth factors negatively regulate collagen genes in smooth muscle of hypertensive rats[J].Hypertension, 1998, 31:986-94
9 Andrew D, Brann G, Jean A, et al.Circulation endothelial cell/ leukocyte adhesion molecules in ischemic disease[J].Br J Haematology, 1996, 95:263-5

[1]	马怡彤, 马建红, 高亚婷, 刘畅. 脂肪细胞因子在子宫内膜癌中的作用及研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1315-1320.
[2]	黄好, 贾虹, 王晓霜, 张鹭, 蒋华. 负载MAGE-A3抗原的树突状细胞与细胞因子诱导杀伤细胞共培养对子宫内膜癌肿瘤干细胞及恶性进展的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 42-50.
[3]	王琦, 邹云增. 冠心病降脂治疗新进展——Evinacumab[J]. 中国临床药理学与治疗学, 2022, 27(4): 362-364.
[4]	王琦, 邹云增. 冠心病降脂治疗新进展——Inclisiran[J]. 中国临床药理学与治疗学, 2022, 27(4): 365-368.
[5]	王琦, 邹云增. 冠心病降脂治疗新进展——贝派地酸[J]. 中国临床药理学与治疗学, 2022, 27(4): 369-372.
[6]	常书福. 冠心病药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 405-408.
[7]	王瑞杰, 王亮, 徐丹, 周淼淼, 李纪明. PCSK9抑制剂对冠心病患者血脂及炎症因子的影响[J]. 中国临床药理学与治疗学, 2022, 27(4): 409-417.
[8]	闫磊, 蒋海彬, 娜菲莎·帕尔哈提, 热孜宛古丽·伊克木, 耿博宇, 麦尔哈巴·麦麦提艾力. 不同剂量右美托咪定对冠心病患者非心脏手术应激及术后睡眠影响[J]. 中国临床药理学与治疗学, 2022, 27(12): 1340-1346.
[9]	卢希娅, 李玉星, 李文智, 彭园园, 胡宜, 万李, 陈碧莲. 老年医学科冠心病患者抗血小板药物服用情况的调查分析[J]. 中国临床药理学与治疗学, 2022, 27(11): 1285-1291.
[10]	何秀娟, 马慧可, 刘青武, 陈佳, 林燕, 李萍. 细胞因子在创面修复中的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(5): 579-585.
[11]	陈力方, 王博, 王维蓉. 组蛋白去乙酰化酶3在心血管疾病中的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(1): 88-97.
[12]	吴加元，郑丽，莫娟芬，郭丽，曹晨曦，鲍轶. N-乙酰半胱氨酸调控非酒精性脂肪性肝病小鼠外周循环及肝脏局部髓源抑制细胞的研究[J]. 中国临床药理学与治疗学, 2019, 24(9): 989-996.
[13]	李敏，王珊珊，刘中和，姜德国. p38MAPK信号通路在慢性牙髓炎疼痛大鼠中的表达及作用机制研究[J]. 中国临床药理学与治疗学, 2019, 24(6): 644-649.
[14]	卜璋于，吴黎明，俞小虹，刘珏，邓琳. 柴胡解毒汤治疗尖锐湿疣的疗效观察和机制探讨[J]. 中国临床药理学与治疗学, 2019, 24(6): 681-686.
[15]	翟硕，李娜，陈蓓宁，寇俊萍，邢为藩，张评浒. 水飞蓟在治疗慢性肝炎中的研究进展[J]. 中国临床药理学与治疗学, 2019, 24(5): 573-579.